Chlorhexidine + Climbazole + Phytosphingosine

Verify with FDA CVM →

14 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
14
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

ChlorhexidineClimbazolePhytosphingosine

Administration Routes

Topical

Species Affected

Dog 13
Cat 1

Most Affected Breeds

Bulldog - French 3
Crossbred Canine/dog 2
Dog (other) 1
Terrier - Cairn 1
Sphynx 1
Spitz - German Pomeranian 1
Shih Tzu 1
Maltese 1
Chihuahua 1
Mixed (Dog) 1

Most Reported Reactions

Erythema (for urticaria see Immune SOC) 6
Pruritus 5
Hair coat discolouration 4
Skin irritation 2
Application site weeping (see also 'skin') 1
Rash 1
Application site rash 1
Lack of efficacy - NOS 1
Behavioural disorder NOS 1
Discomfort NOS 1
Vocalisation 1
Application site scratching 1

Outcome Breakdown

Recovered/Normal
6 (42.9%)
Outcome Unknown
6 (42.9%)
Recovered with Sequela
2 (14.3%)

Data Summary

Metric Value
Total adverse event reports 14
Reports involving death 0
Case-fatality rate (reported events) 0.0%
Distinct species in reports 2
Distinct breeds in reports 11
Distinct reactions reported 20
Active ingredients on file 3

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Chlorhexidine + Climbazole + Phytosphingosine Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 14 adverse event reports referencing Chlorhexidine + Climbazole + Phytosphingosine, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Chlorhexidine, Climbazole, Phytosphingosine. Reported administration route is Topical. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Chlorhexidine + Climbazole + Phytosphingosine reports are Dog (13 reports), Cat (1 reports), with Dog accounting for the largest share. Within those species, Bulldog - French (3), Crossbred Canine/dog (2), Dog (other) (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Chlorhexidine + Climbazole + Phytosphingosine are Erythema (for urticaria see Immune SOC) (6), Pruritus (5), Hair coat discolouration (4), Skin irritation (2). Of the 14 reports with a coded outcome, Recovered/Normal is the leading category at 42.9%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Chlorhexidine + Climbazole + Phytosphingosine.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial